display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced UC (mUC) - 1st Line (L1)
mUC - L1 - all population
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone IMvigor-130 ...
atezolizumab plus SoC IMvigor-130 ...
durvalumab based treatment
durvalumab alone DANUBE ...
pembrolizumab based treatment
pembrolizumab alone KEYNOTE-361 ...
pembrolizumab plus SoC KEYNOTE-361 ...
Immune checkpoint association
durvalumab plus tremelimumab DANUBE ...

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons